How HEOR May Be Used in Conjunction With Real-World Evidence

Community oncology practices looking to implement cellular therapy programs have a "daunting" task ahead of them, says Casey Chollet-Lipscomb, MD.

Community oncology practices are “left guessing” when it comes to “noticeable” challenges with direct and indirect remuneration fees, says Kathy Oubre, MS.

As a fellow, engaging with community oncologists provides valuable mentorship, networking, and career opportunities, explains Tyler Fugere, MD.

Johnetta Blakely, MD, MS, MMHC, explains how collaborations are instrumental in “moving the needle forward” when it comes to community oncology concerns.

Declining reimbursements from manufacturers and PBM issues are “starting to cripple certain community oncology practices,” explains Kirollos S. Hanna, PharmD.

Glenn Balasky, executive director of Rocky Mountain Cancer Centers in Colorado, describes emerging challenges in reimbursement for community oncology practices.

“They wanted to try to cancel our group out,” said Moshe Chasky, MD, describing how a hospital partnership led to a community oncology practice filing a lawsuit.

Lalan Wilfong, MD, details some of the biggest challenges associated with EOM in specific and value-based oncology care in general.

Miriam J. Atkins, MD, president of COA, explains how focusing on PBMs, 340B abuse, and vertical integration is making a difference for community oncologists.

As far as AI use in community oncology, “I just don’t think we’re attracting the right attention,” says Alti Rahman, AON’s chief strategy and innovation officer.

Ben Jones, VP of government relations and public policy at The US Oncology Network, explains policy changes that may "significantly disrupt" community oncology.

Oncologists interested in healthcare innovation often choose between clinical practice and leaving medicine to pursue business. A new option may change that.